SanjayJ.MathewMD

Professor; and Chair for Research in Psychiatry, Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine. Staff Physician, Michael E. Debakey Veterans Affairs Medical Center.

Join to view full profile

Dr. Mathew is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mathew's full profile

Already have an account?

Office
1977 Butler Boulevard
Suite E4.189
Houston, TX 77030
Phone+1 713-798-5877

Education & Training

New York Presbyterian Hospital (Columbia Campus)/New York State Psychiatric InstituteResidency, Psychiatry, 1997 - 2001
Baylor College of MedicineClass of 1997

Certifications & Licensure

NY State Medical License 1998 - 2025
TX State Medical License 2010 - 2025
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Research Study for Major Depressive Disorder: Investigation of Glutamate Medications Start of enrollment: 2006 Dec 01
Completed
Phase 4
Staccato Alprazolam in Panic Attack Start of enrollment: 2007 May 01
Completed
Phase 2
Optimization of IV Ketamine for Treatment Resistant Depression Start of enrollment: 2008 Nov 01
Completed
Phase 2
Efficacy and Tolerability of Riluzole in Treatment Resistant Depression Start of enrollment: 2011 Jun 01
Completed
Phase 2
Fast-Fail Trials in Mood and Anxiety Spectrum Disorders; Kappa Opioid Receptor Phase 2a Start of enrollment: 2015 Jun 01
Completed
Phase 2
Study to Treat Major Depressive Disorder With a New Medication Start of enrollment: 2017 Sep 25
Completed
Phase 2
Ketamine in Veterans With Gulf War Illness Start of enrollment: 2021 Feb 01
Terminated
Early Phase 1
XEN1101 for Major Depressive Disorder Start of enrollment: 2021 Oct 19
COMPLETED
PHASE2
Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan Start of enrollment: 2023 Oct 01
ENROLLING_BY_INVITATION
PHASE4
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Patient preference effects in a randomized comparative effectiveness study of electroconvulsive therapy and ketamine for treatment resistant depression: An ELEKT-D tri...
Gerard Sanacora, Brian S Barnett, Bo Hu, Fernando S Goes, Sanjay J Mathew
Psychiatry Research. 2025-05-01
Functional connectivity subtypes during a positive mood induction: Predicting clinical response in a randomized controlled trial of ketamine for treatment-resistant de...
Shabnam Hossein, Mary L Woody, Benjamin Panny, Crystal Spotts, Meredith L Wallace
Journal of Psychopathology and Clinical Science. 2025-04-01
Effects of KCNQ potassium channel modulation on ventral tegmental area activity and connectivity in individuals with depression and anhedonia.
Laurel S Morris, Sara Costi, Sara Hameed, Katherine A Collins, Emily R Stern
Molecular Psychiatry. 2025-03-25

Journal Articles

Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)
Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature
Endogenous Opioid System Dysregulation in Depression: Implications for New Therapeutic Approaches
Sanjay Mathew, Jordan F Karp, Nature

Authored Content

F179. Epigenetic Biomarkers in Women with Posttraumatic Stress Disorder After CRF1 Receptor Antagonist TreatmentApril 2018
F179. Epigenetic Biomarkers in Women with Posttraumatic Stress Disorder After CRF1 Receptor Antagonist TreatmentApril 2018

Press Mentions

Matthew Perry’s Death Shines a Harsh Light on Ketamine TreatmentAugust 19th, 2024
Researchers Discover Positive Effects of Intravenous Ketamine for Treatment-Resistant DepressionMay 25th, 2023
Treatment for Anxiety: Medications and OptionsApril 6th, 2023
Join now to see all

Grant Support

2/2 A brief automated neurocognitive training to enhance the real-world impact of ketamine's rapid antidepressant effectBAYLOR COLLEGE OF MEDICINE2024–2029
2/2 A brief automated neurocognitive training to enhance the real-world impact of ketamine's rapid antidepressant effectBAYLOR COLLEGE OF MEDICINE2024–2029
Gamma oscillations as a prognostic marker for ketamine therapy in treatment resistant depressionBAYLOR COLLEGE OF MEDICINE2024–2025
Gamma oscillations as a prognostic marker for ketamine therapy in treatment resistant depressionBAYLOR COLLEGE OF MEDICINE2024–2025
Optimization Of IV Ketamine For Treatment Resistant Major DepressionNational Institute Of Mental Health2010–2012
2/3-Efficacy And Tolerability Of Riluzole In Treatment-Resistant DepressionNational Institute Of Mental Health2010–2012
Optimization Of IV Ketamine For Treatment Resistant Major DepressionNational Institute Of Mental Health2009
Optimization Of IV Ketamine For Treatment Resistant Major DepressionNational Center For Research Resources2009
Continuation Riluzole In Prevention Of Relapse Following Ketamine In DepressionNational Center For Research Resources2007–2009
MRS Neurometabolites In Chronic Fatigue Syndrome, GAD And Healthy VolunteersNational Center For Research Resources2008
Proton MRS Studies In Generalized Anxiety DisorderNational Institute Of Mental Health2004–2008
MRS Neurometabolites In Chronic Fatigue Syndrome, GAD, And Healthy VolunteersNational Center For Research Resources2007
Adenocine Receptor Polymorphisms And Physiologic Response To Caffeine In PDNational Center For Research Resources2006
MRS Neurometabolites In Chronic Fatigue Syndrome, Generalized Anxiety DisorderNational Center For Research Resources2005–2006